Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | TYMP | P19971 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.30 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.30 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22349203 | 0.88 | STING1 (0.38) | HIF1ATYMPKDM4EPOLB | |
| SCHEMBL22349173 | 0.87 | TYMP (0.33) | TYMPSLC29A1 | |
| SCHEMBL20692127 | 0.87 | TYMP (0.33) | TYMPSLC29A1 | |
| SCHEMBL20691331 | 0.86 | P2RY12 (0.38) | P2RY1POLB | |
| SCHEMBL21263983 | 0.80 | TAS1R3 (0.36) | TYMP | |
| SCHEMBL20691298 | 0.78 | AHCY (0.37) | TYMPENPP1P2RY1 | |
| SCHEMBL21263982 | 0.78 | TAS1R3 (0.38) | TYMPSLC29A1 | |
| SCHEMBL20691312 | 0.77 | TYMP (0.39) | TYMPKDM4EP2RY1POLB | |
| SCHEMBL20691336 | 0.75 | RNASEL (0.42) | P2RY1POLB | |
| SCHEMBL20692221 | 0.73 | P2RX3 (0.36) | TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3658565-B1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2022-11-09 | — | — | EP | disclosed |
| WO-2019023459-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-01-31 | — | — | WO | disclosed |